News Daily News MICHELLE Published: Low-Dose Rivaroxaban Cuts VTE Risk After COVID-19 Admission Todd Neale December 29, 2021
News Daily News Apixaban Appears Safer, More Effective Than Rivaroxaban in Medicare Study Todd Neale December 27, 2021
News Daily News FDA Approves Two Additional Indications for Rivaroxaban in Children L.A. McKeown December 21, 2021
News Conference News AHA 2021 Racial/Ethnic Disparities in AF Care Persist Despite Dual VA, Medicare Coverage Todd Neale November 19, 2021
News Daily News Rivaroxaban Again Linked to More Bleeding vs Other DOACs Caitlin E. Cox October 11, 2021
News Features When the Time Comes to Stop Oral Anticoagulation: Options and Obstacles Todd Neale September 28, 2021
News Opinion Editor's Corner ESC 2021 ESC 2021: Trials, Guidelines, and Channel Surfing at This Year’s Virtual Congress Shelley Wood August 19, 2021
News Daily News Therapeutic-Dose Heparin in COVID-19: Who Benefits, Who Doesn’t Shelley Wood August 04, 2021
News Conference News HRS 2021 STROKE-VT: DOACs Cut Cerebrovascular Events After LV Arrhythmia Ablation Todd Neale July 29, 2021
News Conference News ACC 2021 ACTION: Full-Dose Rivaroxaban Doesn’t Help in Hospitalized COVID-19 Todd Neale May 17, 2021
News Conference News EHRA 2021 EHRA Updates Its Popular ‘Practical’ NOAC Guide Todd Neale April 29, 2021
News Daily News Dual Bests Triple Therapy in Nonvalvular AF Patients in RE-DUAL PCI Yael L. Maxwell April 09, 2021
News Daily News Observational Study Supports Continuing Oral Anticoagulation During PCI Michael O'Riordan April 06, 2021